All change at the top for Sosei

12 December 2018

Japanese biotech firm Sosei Group (TYO: 4565) today announced that its board of directors, at a meeting held on December 11, 2018, approved a change in its president and chief executive (CEO).

It was decided by mutual consent that Peter Bains will step down as president and CEO of the company on December 31, 2018. Mr Bains will also resign as a director of the company simultaneously.

Shinichi Tamura, executive chairman, founder and former CEO of Sosei, has been appointed as chairman, president and CEO effective as of January 1, 2019. The re-appointment of Mr Tamura as CEO provides a seamless transition that enables the company to continue pursuing its strategic plan, aiming to realize its vision to be a leading Japan-based biotech champion delivering innovative medicines for patients worldwide.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK